Nektar Therapeutics (NKTR) Operating Expenses (2010 - 2026)

Nektar Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 92.23% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $278.5 million (up 87.61% YoY), while the FY2025 annual figure was $195.3 million, down 4.07% from the prior year.
• Operating Expenses was $4.3 million for Q1 2026 at Nektar Therapeutics, down from $183.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $183.4 million in Q4 2025 to a low of $4.3 million in Q1 2026.
• Historically, Operating Expenses has averaged $76.8 million across 5 years, with a median of $69.0 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses jumped 1136.82% in 2025, then plunged 92.23% in 2026.
• A 5-year view of Operating Expenses shows it stood at $74.5 million in 2022, then decreased by 22.95% to $57.4 million in 2023, then slumped by 74.17% to $14.8 million in 2024, then surged by 1136.82% to $183.4 million in 2025, then plunged by 97.67% to $4.3 million in 2026.
• The last three Operating Expenses figures came in at $4.3 million (Q1 2026), $183.4 million (Q4 2025), and $43.5 million (Q3 2025), per Business Quant data.